Biermasz NR - Search Results

1

Consensus on diagnosis and management of Cushing's disease: a guideline update.

Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK. Fleseriu M, et al. Among authors: biermasz nr. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20. Lancet Diabetes Endocrinol. 2021. PMID: 34687601 Free PMC article. Review.

2

Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly.

Biermasz NR, Pereira AM, Frölich M, Romijn JA, Veldhuis JD, Roelfsema F. Biermasz NR, et al. Am J Physiol Endocrinol Metab. 2004 Jan;286(1):E25-30. doi: 10.1152/ajpendo.00230.2003. Epub 2003 Sep 23. Am J Physiol Endocrinol Metab. 2004. PMID: 14506078 Free article. Clinical Trial.

3

Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease.

Pereira AM, van Aken MO, van Dulken H, Schutte PJ, Biermasz NR, Smit JW, Roelfsema F, Romijn JA. Pereira AM, et al. Among authors: biermasz nr. J Clin Endocrinol Metab. 2003 Dec;88(12):5858-64. doi: 10.1210/jc.2003-030751. J Clin Endocrinol Metab. 2003. PMID: 14671181

4

Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.

van Thiel SW, Romijn JA, Biermasz NR, Ballieux BE, Frölich M, Smit JW, Corssmit EP, Roelfsema F, Pereira AM. van Thiel SW, et al. Among authors: biermasz nr. Eur J Endocrinol. 2004 Apr;150(4):489-95. doi: 10.1530/eje.0.1500489. Eur J Endocrinol. 2004. PMID: 15080778 Clinical Trial.

5

Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.

Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F. Biermasz NR, et al. Clin Endocrinol (Oxf). 2004 May;60(5):568-75. doi: 10.1111/j.1365-2265.2004.02021.x. Clin Endocrinol (Oxf). 2004. PMID: 15104559 Clinical Trial.

6

Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements.

Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F. Biermasz NR, et al. J Clin Endocrinol Metab. 2004 Jun;89(6):2789-96. doi: 10.1210/jc.2003-032041. J Clin Endocrinol Metab. 2004. PMID: 15181059

7

Pituitary magnetic resonance imaging is not required in the postoperative follow-up of acromegalic patients with long-term biochemical cure after transsphenoidal surgery.

Zirkzee EJ, Corssmit EP, Biermasz NR, Brouwer PA, Wiggers-De Bruine FT, Kroft LJ, Van Buchem MA, Roelfsema F, Pereira AM, Smit JW, Romijn JA. Zirkzee EJ, et al. Among authors: biermasz nr. J Clin Endocrinol Metab. 2004 Sep;89(9):4320-4. doi: 10.1210/jc.2003-032141. J Clin Endocrinol Metab. 2004. PMID: 15356027

8

Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess.

Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, Romijn JA, Roelfsema F. Biermasz NR, et al. J Clin Endocrinol Metab. 2004 Nov;89(11):5369-76. doi: 10.1210/jc.2004-0669. J Clin Endocrinol Metab. 2004. PMID: 15531483

9

Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance.

Pereira AM, Biermasz NR, Roelfsema F, Romijn JA. Pereira AM, et al. Among authors: biermasz nr. Treat Endocrinol. 2005;4(1):43-53. doi: 10.2165/00024677-200504010-00005. Treat Endocrinol. 2005. PMID: 15649100 Review.

10

High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma.

Pereira AM, Schmid EM, Schutte PJ, Voormolen JH, Biermasz NR, van Thiel SW, Corssmit EP, Smit JW, Roelfsema F, Romijn JA. Pereira AM, et al. Among authors: biermasz nr. Clin Endocrinol (Oxf). 2005 Feb;62(2):197-204. doi: 10.1111/j.1365-2265.2004.02196.x. Clin Endocrinol (Oxf). 2005. PMID: 15670196 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

286 results

Search Page